Last 48 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Alnylam Pharmaceuticals, Inc.'s quarterly P/E stands at 72.6x.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 142.88 | 72.56 | 61.96 | — | — | — | — | — | — | — | 38.50 | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 11.87 | 12.35 | 12.54 | 13.66 | 14.73 | 12.75 | 17.65 | 11.67 | 9.53 | 13.67 | 7.75 | 18.57 | 19.47 |
| — | -3.2% | -29.0% | +17.1% | +54.5% | -6.7% | +127.8% | -37.2% | -51.0% | -37.5% | -66.5% | -5.3% | -15.5% | |
| P/B Ratio | 56.82 | 68.67 | 267.77 | 168.75 | 303.33 | 451.03 | 1093.10 | — | — | — | — | — | — |
| — | -84.8% | -75.5% | — | — | — | — | — | — | — | — | — | — | |
| P/FCF | 94.70 | 96.59 | 50.03 | 75.82 | — | — | 223.75 | 66.29 | — | — | 16.99 | — | — |
| — | — | -77.6% | +14.4% | — | — | +1217.2% | — | — | — | — | — | — | |
| EV / EBITDA | 81.44 | 95.55 | 41.85 | — | 282.60 | — | — | 127.86 | — | — | 25.90 | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | 90.48 | 105.35 | 56.39 | 2245.91 | — | — | — | 368.20 | — | — | 32.39 | — | — |
| — | — | — | +510.0% | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Alnylam Pharmaceuticals, Inc.'s operating margin was 12.0% in Q4 2025, down 17.5 pp QoQ and up 29.7 pp YoY. The trailing four-quarter average of 10.6% lags the current quarter, suggesting the recent improvement is above-trend. Gross margin contracted 8.0% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 81.8% | 76.0% | 84.2% | 81.5% | 88.0% | 82.7% | 82.9% | 89.6% | 86.7% | 80.5% | 88.8% | 73.2% | 82.8% |
| — | -8.0% | +1.6% | -9.0% | +1.6% | +2.7% | -6.7% | +22.4% | +4.6% | -5.0% | +5.1% | -10.5% | -0.6% | |
| Operating Margin | 13.5% | 12.0% | 29.5% | -2.1% | 3.0% | -17.7% | -15.4% | 7.4% | -8.8% | -26.5% | 28.5% | -72.1% | -46.9% |
| — | +167.7% | +291.9% | -128.4% | +134.6% | +33.0% | -153.9% | +110.2% | +81.3% | +53.0% | +129.2% | +15.4% | +31.8% | |
| Net Margin | 8.4% | 17.0% | 20.1% | -8.6% | -9.7% | -14.1% | -22.3% | -2.6% | -13.3% | -31.4% | 19.7% | -86.6% | -54.5% |
| — | +220.3% | +190.3% | -234.7% | +27.5% | +55.0% | -213.1% | +97.0% | +75.5% | +49.4% | +112.8% | +29.8% | +51.6% |
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 73.3% | 36.4% | 103.6% | -36.2% | -63.0% | -168.5% | -761.9% | — | — | — | — | — | — |
| — | +121.6% | +113.6% | — | — | — | — | — | — | — | — | — | — | |
| ROA | 6.8% | 3.8% | 5.3% | -1.5% | -1.4% | -2.0% | -2.7% | -0.4% | -1.7% | -3.6% | 4.1% | -8.1% | -5.0% |
| — | +291.4% | +296.3% | -250.1% | +21.1% | +44.8% | -166.6% | +94.7% | +65.7% | +38.6% | +134.5% | +0.9% | +26.1% | |
| ROIC | 19.1% | 5.1% | 15.3% | -0.7% | 0.7% | -4.5% | -3.4% | 2.1% | -1.9% | -9.9% | 89.5% | -54.1% | -32.8% |
| — | +214.2% | +549.2% | -131.7% | +139.0% | +54.6% | -103.8% | +103.8% | +94.2% | +83.2% | +279.0% | -173.6% | -142.9% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Alnylam Pharmaceuticals, Inc.'s Debt/EBITDA ratio is 20.4x, up from 7.8x last quarter — elevated, raising questions about debt serviceability.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 3.76 | 3.76 | 12.81 | 10.93 | 23.58 | 40.89 | 84.26 | — | — | — | — | — | — |
| — | -90.8% | -84.8% | — | — | — | — | — | — | — | — | — | — | |
| Debt / EBITDA | 5.33 | 20.44 | 7.85 | — | 83.81 | — | — | 42.57 | — | — | 5.76 | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 2.76 | 2.76 | 2.54 | 2.80 | 3.04 | 2.78 | 2.75 | 3.01 | 3.17 | 3.08 | 3.14 | 3.20 | 3.77 |
| — | -0.6% | -7.6% | -6.8% | -4.3% | -9.9% | -12.5% | -6.1% | -15.9% | -12.1% | -9.7% | -14.8% | -11.7% | |
| Quick Ratio | 2.71 | 2.71 | 2.49 | 2.75 | 2.98 | 2.71 | 2.69 | 2.93 | 3.07 | 2.99 | 3.04 | 3.07 | 3.58 |
| — | -0.2% | -7.2% | -6.2% | -3.1% | -9.3% | -11.7% | -4.8% | -14.1% | -10.4% | -8.7% | -15.2% | -13.7% | |
| Interest Coverage | — | — | 8.29 | -0.40 | 0.47 | -2.70 | -2.24 | 1.46 | -1.23 | -3.71 | 6.92 | -7.65 | -5.17 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonAlnylam Pharmaceuticals, Inc.'s current P/E is 142.9x. The average P/E over the last 2 quarters is 67.3x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Alnylam Pharmaceuticals, Inc.'s current operating margin is 13.5%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Alnylam Pharmaceuticals, Inc.'s business trajectory between earnings reports.